Description: Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. It has strategic alliances and commercial agreements with Ovamed GmbHp; Dr. Falk Pharma GmbH; and Freie Universität Berlin. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in Burlington, Massachusetts.
Home Page: www.fortressbiotech.com
FBIO Technical Analysis
1111 Kane Concourse
Bay Harbor Islands,
FL
33154
United States
Phone:
781 652 4500
Officers
| Name | Title |
|---|---|
| Dr. Lindsay Allan Rosenwald | Exec. Chairman, Pres & CEO |
| Mr. Michael S. Weiss Esq. | Vice Chairman & Exec. Vice Chairman of Strategic Devel. |
| Dr. George C. Avgerinos | Sr. VP of Biologics Operations |
| Ms. Robyn M. Hunter | Exec. Officer |
| Mr. David Jin | CFO & Head of Corp. Devel. |
| Mr. Samuel Berry | Gen. Counsel & Corp. Sec. |
| Dr. Thomas F. Schaible | Project Leader of Inflammatory Bowel Disease |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0999 |
| Price-to-Sales TTM: | 0.8248 |
| IPO Date: | 2011-11-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 173 |